Viridian Therapeutics, Inc.\DE (VRDN) Gains from Investment Securities (2016)
Viridian Therapeutics, Inc.\DE's (VRDN) quarterly Gains from Investment Securities came in at $1000.0 in Q4 2016, up 125.0% quarter-over-quarter from -$4000.0 in Q3 2016.
Viridian Therapeutics, Inc.\DE (VRDN) Gains from Investment Securities (2016) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Gains from Investment Securities history runs 1 years deep, the most recent figure standing at $1000.0 for Q4 2016.
- On a quarterly basis, Gains from Investment Securities changed N/A year-over-year to $1000.0 in Q4 2016; TTM through Dec 2017 was -$3000.0, a N/A change from a year earlier, with the FY2016 full-year figure at $3000.0, changed N/A from the prior year.
- Gains from Investment Securities climbed to $1000.0 in Q4 2016 per VRDN's latest filing, from -$4000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $1000.0 in Q4 2016 and bottomed at -$4000.0 in Q3 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Viridian Therapeutics, Inc.\DE | 655.26 Mn | 655.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 1,000.00 |
| Dec 31, 2016 | 1,000.00 |
| Sep 30, 2016 | -4,000.00 |
| Sep 30, 2016 | -4,000.00 |